Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2023, 5(3); doi: 10.25236/IJFM.2023.050301.

Pan-carcinogenic analysis of Annexin A1 gene in human tumors: A bioinformatics study


Yuepeng Wang1, Su Yang1, Pengfei Han2, Shilei Qin3, Yunfeng Xu3

Corresponding Author:
Yunfeng Xu

1Department of Graduate School, Graduate Student Department of Changzhi Medical College, Changzhi, China

2Department of Orthopaedics, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China

3Department of Orthopaedics, Changzhi Yunfeng Hospital, Changzhi, China


Background: Annexin A1 (ANXA1) and cancer appear to be related, based on emerging cell-based or animal research, but pan-cancer analysis is lacking. Objective: By using bioinformatics, we will examine the expression characteristics of the ANXA1 gene in pan-cancers. Methods: In collaboration with TCGA and GEO database, ANXA1 gene was analyzed pan-cancer, and through gene expression analysis, survival analysis, gene variation, immune infiltration, and enrichment analysis, ANXA1 played a role in the pathogenesis of different tumors. Results: A significant correlation has been found between ANXA1 expression and prognosis in some patients with tumors. The expression level of ANXA1 was correlated with the pathological stage of head and neck squamous cell carcinoma (HNSC) and thyroid carcinoma (THCA). The survival rates are related to the expression level of ANXA1 in different tumors. There is a strong correlation between the expression of ANXA1 and immune cell infiltration in some tumors and patients with sarcoma (SARC) and uterine corpus endometrial carcinoma (UCEC) have a higher mutation and amplification rate for the ANXA1 gene. ANXA1 may participate in the occurrence and development of tumor through "proteoglycans in cancer" signal pathways. Conclusion: The ANXA1 gene is involved in the pathogenesis of multiple kinds of tumors, and the study of its pathogenic mechanism may be an effective approach to treating tumors.


ANXA1; bioinformatics; tumor; gene expression; immune infiltration

Cite This Paper

Yuepeng Wang, Su Yang, Pengfei Han, Shilei Qin, Yunfeng Xu. Pan-carcinogenic analysis of Annexin A1 gene in human tumors: A bioinformatics study. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 3: 1-7. https://doi.org/10.25236/IJFM.2023.050301.


[1] Iseki Y, Imoto A, Okazaki T, Harigae H, Takahashi S. Identification of annexin 1 as a PU.1 target gene in leukemia cells [J]. Leuk Res. 2009; 33(12):1658-1663.

[2] Li YZ, Wang YY, Huang L, Zhao YY, Chen LH, Zhang C. Annexin A protein family in atherosclerosis [J]. Clin Chim Acta. 2022; 531:406-417.

[3] Rescher U, Gerke V, Lim LHK, Jaiswal JK. Special Issue "Recent Developments in Annexin Biology"[J]. Cells. 2020; 9(11):2477.

[4] Xi Y, Ju R, Wang Y. Roles of Annexin A protein family in autophagy regulation and therapy [J]. Biomed Pharmacother. 2020; 130:110591. 

[5] Guan X, Fang Y, Long J, Zhang Y. Annexin 1-nuclear factor-κB-microRNA-26a regulatory pathway in the metastasis of non-small cell lung cancer [J]. Thorac Cancer. 2019; 10(4):665-675.

[6] McArthur S, Juban G, Gobbetti T, et al. Annexin A1 drives macrophage skewing to accelerate muscle regeneration through AMPK activation[J]. J Clin Invest. 2020; 130(3):1156-1167.

[7] Chen R, Chen C, Han N, et al. Annexin-1 is an oncogene in glioblastoma and causes tumour immune escape through the indirect upregulation of interleukin-8[J]. J Cell Mol Med. 2022; 26(15):4343-4356.

[8] Bai F, Zhang P, Fu Y, et al. Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer [J]. J Immunother Cancer. 2020; 8(1): e000169.

[9] Prates J, Moreli JB, Gimenes AD, et al. Cisplatin treatment modulates Annexin A1 and inhibitor of differentiation to DNA 1 expression in cervical cancer cells[J]. Biomed Pharmacother. 2020; 129:110331.

[10] Yamanoi M, Yamanoi K, Fujii C, Fukuda MN, Nakayama J. Annexin A1 expression is correlated with malignant potential of renal cell carcinoma [J]. Int J Urol. 2019; 26(2):284-290.

[11] Juban G, Mounier R. Réparation. Tissue repair: Key role of annexin A1 in the control of inflammatory response [J]. Med Sci (Paris). 2021; 37(4):324-326.

[12] Baracco EE, Petrazzuolo A, Kroemer G. Assessment of annexin A1 release during immunogenic cell death [J]. Methods Enzymol. 2019; 629:71-79.

[13] Costa MB, Mimura KKO, Freitas AA, et al. Mast cell heterogeneity and anti-inflammatory annexin A1 expression in leprosy skin lesions[J]. Microb Pathog. 2018; 118:277-284.

[14] Shijo M, Hamasaki H, Honda H, et al. Upregulation of Annexin A1 in Reactive Astrocytes and Its Subtle Induction in Microglia at the Boundaries of Human Brain Infarcts[J]. J Neuropathol Exp Neurol. 2019; 78(10):961-970.

[15] Li X, Xia Q, Mao M, et al. Annexin-A1 SUMOylation regulates microglial polarization after cerebral ischemia by modulating IKKα stability via selective autophagy [J]. Sci Adv. 2021;7(4): eabc5539.

[16] Li P, Li L, Li Z, et al. Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway [J]. Cancer Cell Int. 2022; 22(1):7.

[17] Kotepui KU, Obchoei S, Vaeteewoottacharn K, Okada S, Wongkham S, Sawanyawisuth K. Annexin A1 Is a Potential Prognostic Marker for, and Enhances the Metastasis of, Cholangiocarcinoma[J]. Asian Pac J Cancer Prev. 2022; 23(2):715-721.

[18] Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer[J]. Nat Rev Cancer. 2018;18(12):744-757.

[19] Xu X, Gao W, Li L, et al. Annexin A1 protects against cerebral ischemia-reperfusion injury by modulating microglia/macrophage polarization via FPR2/ALX-dependent AMPK-mTOR pathway [J]. J Neuroinflammation. 2021; 18(1):119.

[20] Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges [J]. Cell Biosci. 2020; 10:31.

[21] Duval AP, Jeanneret C, Santoro T, Dormond O. mTOR and Tumor Cachexia[J]. Int J Mol Sci. 2018; 19(8):2225.